Clinical trial NCT00175695: Disease Modification in Toxaemia of Pregnancy
Official title: A Safety and Efficacy Trial of Recombinant Human Activated Protein C in Both Early-onset Pre-eclampsia and Severe Postpartum Pre-eclampsia.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pre-eclampsia
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2005-09-15
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women with pre-eclampsia ('toxaemia of pregnancy').

Brief summary: Short description of the primary purpose of the protocol intended for the lay public. Include brief statement of study hypothesis

Pre-eclampsia (toxemia of pregnancy) is the most cause of death among pregnant women in North America. It also causes many complications for fetuses (unborn children) and neonates (newborn children). Pre-eclampsia is defined by high blood pressure (hypertension), the loss of protein into the urine (proteinuria), and disorders of many body systems, including the blood clotting (coagulation) and inflammation. What is needed is a compound that will safely prolong pregnancies, to give babies more time to grow inside their mothers, and will help the recovery in those mothers after delivery.

We are going to investigate a compound (recombinant human activated protein C (rhAPC)) that has the potential to modify disease activity in pre-eclampsia by reducing coagulation and inflammation disorders. rhAPC is effective in patients suffering from septic shock. We will test rhAPC in women who develop severe pre-eclampsia in two ways. First, in women with severe pre-eclampsia remote from term who are carrying small babies (intent: safely prolong their pregnancies). Second, in women who have had severe pre-eclampsia before their baby delivered (including women in the first group), or whose disease develops/worsens after delivery (intent: switch off the disease so dangerous complications do not arise).

This study is a preliminary one to look for possible risks and benefits for these women. Only 40 women will be studied to provide initial evidence on which to base a larger international trial which is planned. We will study their pregnancy outcomes as well as markers of disease activity, to gain a better understanding of the mechanisms by which these women become unwell.


Eligibility criteria: Inclusion Criteria:

* Scenario 1 is severe early-onset pre-eclampsia, where the fetal prognosis is dismal (\<50% chance of intact survival \[disease onset \<27+0 weeks gestation and/or estimated fetal weight \<600g\].
* Scenario 2 is postpartum pre-eclampsia, where there is either severe antenatal disease, deteriorating postpartum disease, or de novo postpartum disease.

Exclusion Criteria:

-

Primary outcomes:
measure: Antenatal: The primary safety outcome will be the incidence of peripartum bleeding, The primary efficacy outcome will be days of pregnancy prolongation
timeFrame: Unknown at this time
measure: Postnatal: The primary safety outcome will be the incidence of postpartum bleeding. The primary efficacy outcome will be 'days alive and free of illness'
timeFrame: Unknown at this time
Secondary outcomes:
measure: We will assess disease activity (as measured by clinical and basic science indices).
timeFrame: Unknown at this time
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: BC Women's Hospital and Health Centre
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Peter von Dadelszen, MD
role: PRINCIPAL_INVESTIGATOR
References: